# Genmab clinical trials: 72 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 72 trials with Genmab as lead sponsor, 15 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Genmab: 72 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/genmab

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 72
- Recruiting or not yet: 15
- Read on: November 19, 2026

## Trials

The 25 newest of 72, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 5, 2026 | NCT07859215 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line... | Genmab | Phase 3 | Not yet recruiting | Ovarian Cancer | 602 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859215) |
| August 20, 2026 | NCT07775287 | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent... | Genmab | Phase 3 | Recruiting | Colorectal Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775287) |
| July 14, 2026 | NCT07702032 | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic... | Genmab | Phase 3 | Recruiting | Left-sided Colorectal Cancer | 960 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702032) |
| July 10, 2026 | NCT07695831 | A Phase 1 Trial of GEN1119 in Participants With Solid Tumors | Genmab | Phase 1 | Recruiting | Solid Tumours | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695831) |
| May 22, 2026 | NCT07604766 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant... | Genmab | Phase 3 | Recruiting | Platinum-resistant Ovarian Cancer | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604766) |
| May 4, 2026 | NCT07564141 | Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based... | Genmab | Phase 3 | Recruiting | Platinum-Sensitive Ovarian Cancer, Ovarian Cancer | 688 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564141) |
| April 20, 2026 | NCT07539311 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers | Genmab | Phase 2 | Recruiting | Gastrointestinal Cancers | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539311) |
| February 17, 2026 | NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | Genmab | Phase 1 | Recruiting | Solid Tumors, Urothelial Carcinoma | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416123) |
| February 4, 2026 | NCT07387068 | Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors | Genmab | Phase 1 | Recruiting | Advanced Solid Tumors | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387068) |
| February 3, 2026 | NCT07384715 | First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome... | Genmab | Phase 1 | Recruiting | R/R AML, R/R HR-MDS, Acute Myeloid Leukemia, Higher-Risk Myelodysplastic Syndrome | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07384715) |
| January 21, 2026 | NCT07353957 | Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer | Genmab | Phase 2 | Withdrawn | Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07353957) |
| December 17, 2025 | NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer | Genmab | Phase 2 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288177) |
| November 10, 2025 | NCT07226752 | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in... | Genmab | Phase 3 | Active not recruiting | Diffuse Large B-Cell Lymphoma | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226752) |
| November 6, 2025 | NCT07225270 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of... | Genmab | Phase 3 | Recruiting | Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC | 544 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225270) |
| September 10, 2025 | NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Genmab | Phase 3 | Recruiting | Endometrial Cancer, Recurrent or Progressive Endometrial Cancer | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166094) |
| May 22, 2025 | NCT06984328 | Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned... | Genmab | Phase 2 | Terminated | Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic... | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06984328) |
| January 13, 2025 | NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | Genmab | Phase 1/2 | Terminated | Malignant Solid Tumor | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06771921) |
| November 12, 2024 | NCT06685068 | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | Genmab | Phase 1/2 | Terminated | Advanced Solid Tumor | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06685068) |
| October 10, 2024 | NCT06635824 | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer... | Genmab | Phase 3 | Active not recruiting | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | 191 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06635824) |
| October 1, 2024 | NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Genmab | Phase 3 | Active not recruiting | Platinum-resistant Ovarian Cancer | 584 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06619236) |
| August 27, 2024 | NCT06573294 | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors | Genmab | Phase 1 | Terminated | Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06573294) |
| July 29, 2024 | NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Genmab | Phase 3 | Active not recruiting | Head and Neck Squamous Cell Carcinoma | 699 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06525220) |
| July 18, 2024 | NCT06508658 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV... | Genmab | Phase 3 | Active not recruiting | Diffuse Large B-Cell Lymphoma | 379 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06508658) |
| July 11, 2024 | NCT06496178 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell... | Genmab | Phase 3 | Active not recruiting | Head and Neck Squamous Cell Carcinoma | 621 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06496178) |
| April 30, 2024 | NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | Genmab | Phase 1/2 | Terminated | Malignant Solid Tumor | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06391775) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 29 |
| Phase 2 | 14 |
| Phase 2/3 | 1 |
| Phase 3 | 18 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Terminated | 23 |
| Active not recruiting | 20 |
| Recruiting | 14 |
| Completed | 10 |
| Withdrawn | 3 |
| Not yet recruiting | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lymphoma, Large B-Cell, Diffuse | 13 |
| Ovarian Neoplasms | 9 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Neoplasms | 8 |
| Lymphoma, Non-Hodgkin | 8 |
| Squamous Cell Carcinoma of Head and Neck | 7 |
| Head and Neck Neoplasms | 7 |
| Recurrence | 7 |
| Colorectal Neoplasms | 5 |
| Endometrial Neoplasms | 5 |
| Lymphoma, Follicular | 5 |
| Lymphoma | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
| Triple Negative Breast Neoplasms | 4 |
| Fallopian Tube Neoplasms | 4 |
| Lymphoma, B-Cell, Marginal Zone | 3 |
| Neoplasms, Squamous Cell | 3 |
| Melanoma | 3 |
| Uterine Cervical Neoplasms | 3 |
| Breast Neoplasms | 2 |
| Lymphoma, B-Cell | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Stomach Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
| Carcinoma, Renal Cell | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cheesesteak restaurants in the United States](https://specstream.ai/data/businesses/cheesesteak-restaurants/united-states)
- [Cosmetic dentistry practices in the United States](https://specstream.ai/data/businesses/cosmetic-dentistry-practices/united-states)
- [Drive thru bars in the United States](https://specstream.ai/data/businesses/drive-thru-bars/united-states)
- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
- [Food and beverage exporters in the United States](https://specstream.ai/data/businesses/food-and-beverage-exporters/united-states)
- [Hazardous waste disposal companies in the United States](https://specstream.ai/data/businesses/hazardous-waste-disposal-companies/united-states)
